Remimazolam is a novel ultra-short acting benzodiazepine with rapid onset of effects, short maintenance and faster recovery time. Due to its recent development, few studies have investigated the effect of remimazolam on postoperative recovery mainly focusing on physiologic endpoints, recovery time and possible adverse events. Although these parameters are crucial and need evaluation, the investigators ignore quality of recovery from participant's perspective. For this purpose, various measurment tools have been developed for psychometric evaluation of QoR score.

To date, there has not been a study investigating the impact of remimazolam on quality of recovery (QoR). This study evaluates the effect of remimazolam on QoR of participants undergoing general anesthesia using remimazolam-remifentanil total intravenous anesthesia (TIVA) for hysteroscopy as day surgery basis. Herein, the investigators used the translated Korean version of the 15-item Quality of Recovery-15 (QoR-15K) questionnaire, which was previously validated in Korean surgical participants.

Inclusion Criteria:

• Adult woman scheduled for ambulatory gynecological surgery under general anesthesia
• American Society of Anesthesiology grade 1 or 2

Exclusion Criteria:

• Underlying diseases: liver, kidney, brain nervous system, glaucoma
• Patients with BMI greater than 30 and less than 18.5
• Patients diagnosed with sleep apnea
• Alcohol or drug dependent patients
• Patients with severe or acute respiratory failure
• Lactose intolerance
• Dextran 40 hypersensitivity
• Patients in shock or coma

Adult woman scheduled for ambulatory gynecological surgery under general anesthesia